These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 24756800)

  • 1. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA; Talwar S; Yang AS
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R; Almstedt M; Lübbert M
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.